Dermatologic adverse events associated with Juvenile Idiopathic Arthritis treatment
- Autori: J. Smorenburg, M. de Graaf, J. van Straalen, A. Consolaro, A. Belot, E. Alexeeva, V. Vargova, R. Consolini, M. C. Maggio, D. Rigante, R. Abdwani, A. L. Rodriguez Lozano, I. Orban, N. Ruperto, N. Wulffraat, S. de Roock, J. Swart
- Anno di pubblicazione: 2020
- Tipologia: Poster pubblicato in rivista
- OA Link: http://hdl.handle.net/10447/464221
Abstract
Introduction: Steroids and disease-modifying anti-rheumatic drugs (DMARDs) are widely used in the treatment of juvenile idiopathic arthritis (JIA). Dermatologic adverse events including psoriasis have been reported in treatment of various inflammatory diseases (1-3). However, data regarding the occurrence of dermatologic adverse events in JIA patients are scarce (4-6). Objectives: To determine the prevalence of dermatologic adverse events in JIA patients treated with systemic steroids and DMARDs. To investigate an association between drugs and dermatologic adverse events and the association between anti-TNF treatment and psoriasiform lesions.